Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 35104E100 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Janus Henderson Group PLC 13G/A | 10.3% |
4/7/2026
Event 3/31/2026
|
||
|
Biotechnology Value Fund L P
13G/A
|
10.0% |
5/15/2026
Event 3/31/2026
|
||
| Biotechnology Value Fund L P | 7.3% | |||
| BVF I GP LLC | 7.3% | |||
| Biotechnology Value Fund II LP | 2.1% | |||
| BVF II GP LLC | 2.1% | |||
| Biotechnology Value Trading Fund OS LP | 0.6% | |||
| BVF Partners OS Ltd. | 0.6% | |||
| BVF GP Holdings LLC | 9.3% | |||
| BVF Partners L P/IL | 10.0% | |||
| BVF Inc/IL | 10.0% | |||
| Lampert Mark N | 10.0% | |||
|
RA Capital Management, L.P.
13G/A
|
9.9% |
5/15/2026
Event 3/31/2026
|
||
| RA Capital Management, L.P. | 9.9% | |||
| Peter Kolchinsky | 9.9% | |||
| Rajeev Shah | 9.9% | |||
| RA Capital Healthcare Fund, L.P. | 9.9% | |||
|
Goldman Sachs Group Inc
13G/A
|
7.5% |
2/9/2026
Event 12/31/2025
|
||
| The Goldman Sachs Group, Inc. | 7.5% | |||
| Goldman Sachs & Co. LLC | 7.5% | |||
| BlackRock, Inc. 13G/A | 6.6% |
10/17/2025
Event 9/30/2025
|
||
| Novo Holdings A/S 13G/A | 6.4% |
2/17/2026
Event 12/31/2025
|
||
| State Street Corp 13G | 5.3% |
5/12/2026
Event 3/31/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
1.5% |
5/15/2025
Event 3/31/2025
|
||
| Venrock Healthcare Capital Partners III, L.P. | 1.5% | |||
| VHCP Co-Investment Holdings III, LLC | 1.5% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 1.5% | |||
| VHCP Management III, LLC | 1.5% | |||
| VHCP Management EG, LLC | 1.5% | |||
| Nimish Shah | 1.5% | |||
| Bong Y Koh | 1.5% | |||
|
Deep Track Capital, LP
13G/A
|
1.3% |
2/14/2025
Event 12/31/2024
|
||
| Deep Track Capital, LP | 1.3% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 1.3% | |||
| David Kroin | 1.3% | |||
| Vanguard Group Inc 13G/A | 0% |
3/26/2026
Event 3/13/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 5 | 4.90 k | $70.1 k |
| 2026 Q2 | 166 | 58.1 M | $773 M |
| 2026 Q1 | 160 | 50.7 M | $471 M |
| 2025 Q4 | 160 | 53.4 M | $402 M |
| 2025 Q3 | 140 | 40.1 M | $350 M |
| 2025 Q2 | 126 | 40.6 M | $152 M |
| 2025 Q1 | 132 | 43.1 M | $141 M |
| 2024 Q4 | 150 | 46.8 M | $262 M |
| 2024 Q3 | 148 | 58.6 M | $633 M |
| 2024 Q2 | 152 | 59.1 M | $1.24 B |
| 2024 Q1 | 164 | 59.9 M | $1.91 B |
| 2023 Q4 | 121 | 45.2 M | $917 M |
| 2023 Q3 | 116 | 41.9 M | $534 M |
| 2023 Q2 | 106 | 41.2 M | $745 M |
| 2023 Q1 | 99 | 30.4 M | $522 M |
| 2022 Q4 | 106 | 29.5 M | $655 M |
| 2022 Q3 | 92 | 27.5 M | $221 M |
| 2022 Q2 | 93 | 26.0 M | $182 M |
| 2022 Q1 | 84 | 26.2 M | $396 M |
| 2021 Q4 | 82 | 24.7 M | $543 M |
| 2021 Q3 | 64 | 19.2 M | $515 M |
| 2021 Q2 | 58 | 17.0 M | $409 M |
| 2021 Q1 | 66 | 15.8 M | $684 M |
| 2020 Q4 | 53 | 14.6 M | $602 M |